<DOC>
	<DOCNO>NCT02799316</DOCNO>
	<brief_summary>Hepatitis B virus ( HBV ) infection challenge health problem . According World Health Organization , estimate 240 million individual ( 3.7 % ) suffer chronic HBV infection worldwide . After acute hepatitis B virus ( HBV ) infection , disappearance hepatitis B surface antigen ( HBsAg ) generally believe signify viral elimination . However , become clear subject may occult HBV infection define presence HBV DNA liver absence HBsAg serum . Occult HBV infection usually accompany antibody hepatitis B core antigen ( anti-HBc ) and/or antibody HBsAg ( anti-HBs ) , case might serological marker ( seronegative occult HBV infection ) .</brief_summary>
	<brief_title>Is Hepatitis B Surface Antigen ( HB Ag ) Enough Alone Screening Test Before Immunosuppressive Therapies ?</brief_title>
	<detailed_description>In recent systematic review , nearly 40 % HBsAg carriers 5 % antiHBc-positive HBsAg-negative patient develop HBVr TNF inhibitor therapy . Considering lifelong use multiple antirheumatic drug , need specific guideline management rheumatic disease patient schedule receive biological and/or non-biological DMARDs .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>• Any patient rheumatic disease hepatitis B surface antigen negative . • Overt comorbid condition . Any malignancy e.g . HCC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>